Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Francis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Cell
|
January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
Salvador Alonso, Kanwal Raghav, Van K Morris, et al.
JCO Precision Oncology
|
October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2020
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Nathan A Pennell, Melissa Dillmon, Laura A Levit, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Francis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Cell
|
January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
Salvador Alonso, Kanwal Raghav, Van K Morris, et al.
JCO Precision Oncology
|
October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2020
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Nathan A Pennell, Melissa Dillmon, Laura A Levit, et al.
Page
of 3